ACCEL Lite: Omecamtiv Mecarbil and EF in the GALACTIC-HF Trial

In the GALACTIC-HF trial of 8,256 patients with heart failure (HF) and reduced ejection fraction (EF), omecamtiv mecarbil significantly improved the primary endpoint of time to first HF event or cardiovascular death without any adverse effect on blood pressure, heart rate, potassium homeostasis, or renal function and without increases in ischemic cardiac events or arrhythmias. In this interview, Michelle O'Donoghue, MD, FACC; John Teerlink, MD, FACC; and Jeffrey Hsu, MD, PhD, discuss the effect of EF on clinical outcomes in patients treated with omecamtiv mecarbil in the GALACTIC-HF trial.

Like what you hear? ACCEL Subscribers enjoy 20+ insider interviews like these every month, with CME/MOC credit and other exclusive benefits. Subscribe today for more, and check out what's new at www.acc.org/ACCEL.




Clinical Topics: Arrhythmias and Clinical EP, Cardiovascular Care Team, Heart Failure and Cardiomyopathies, Implantable Devices, SCD/Ventricular Arrhythmias, Atrial Fibrillation/Supraventricular Arrhythmias, Acute Heart Failure

Keywords: ACCELLite, Heart Failure, Stroke Volume, Heart Rate, Blood Pressure, Ventricular Dysfunction, Left, Arrhythmias, Cardiac, Homeostasis


< Back to Listings